EarningsQ2 2026 Earnings Report
MX:STVNN Q2 2026 EPS Results
Actual EPS$2.85
Consensus EPS$2.59
Beat/MissBeat by +$0.26
One Year Ago EPS$2.24
MX:STVNN Q2 2026 Revenue Results
Actual Revenue$6.38B
Expected Revenue$6.08B
Beat/MissBeat by +$304.61M
YoY Revenue Growth+10.63%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeBefore Open
Conference CallTuesday, August 4, 2026
MX:STVNN Upcoming Earnings
Stevanato Group's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:STVNN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a generally constructive operational and commercial story: top-line growth (8% y/y), strong expansion of high-value solutions (+16%) and significant adjusted EBITDA and margin improvement. The company announced an important commercial milestone (Alina approvals) and ongoing capacity build-outs that support mid- to long-term value capture in biologics. Offsetting these positives were one-time divestiture costs (EUR 12.2m), negative free cash flow in the quarter, elevated net debt, higher taxes, and caution around elongated sales cycles in Engineering. On balance, the highlights — recurring revenue growth, margin expansion, product approvals and clear capacity investments — outweigh the near-term lowlights tied largely to one-time items and measured execution/timing risks.Company Guidance
Revenue Growth
Total revenue grew 8% year-over-year to EUR 302.0 million in Q2 2026 (reported and constant currency). Growth was driven by the Biopharmaceutical & Diagnostic Solutions (BDS) segment, which rose 9% to EUR 266.2 million.
Expansion of High-Value Solutions
Revenue from high-value solutions increased 16% year-over-year to EUR 135.9 million, representing 45% of total company revenue in Q2 2026 and ~51% of BDS segment revenue. Management highlighted that high-value solutions growth was driven by biologics and premium products.
Adjusted EBITDA and Margin Expansion
Adjusted EBITDA increased 21% to EUR 78.7 million and adjusted EBITDA margin expanded 280 basis points to 26% in Q2 2026. On an adjusted basis, operating profit margin improved ~250 basis points to 18%.
Product & Commercial Milestone: Alina Approval
One pharmaceutical customer received regulatory approval in multiple European countries for a liraglutide-based therapy using Stevanato Group's proprietary Alina variable-dose pen (two variants for diabetes and weight management). Management expects Alina to drive commercial traction and to be produced at the Germany facility; management expects Alina to support double-digit revenue growth in coming periods.
Engineering Segment Operational Progress
Engineering showed marked margin improvement: gross profit margin improved by 540 basis points to 12% and operating profit margin increased 370 basis points to 2.9% in Q2 2026. Management cited stabilization from the optimization plan and progress in winning new orders.
Progress on Growth Investments and Capacity Build-out
Key project milestones: Fishers completed initial performance qualification on first EZ-fill vial line and device program remains on track for commercial production later in 2026; Latina syringe ramp-up ongoing; next-generation RTU 400 cartridge line expected installed soon with commercial production in 2027. Q2 capital expenditures totaled EUR 52 million focussed on new plants and the Alina program.
Updated Full-Year Guidance
Full-year 2026 guidance updated to revenue of EUR 1.260 billion–EUR 1.280 billion, adjusted EBITDA of EUR 335 million–EUR 345.2 million, and adjusted diluted EPS of EUR 0.60–EUR 0.62. High-value solutions expected to reach 47%–48% of total revenue for the year.
MX:STVNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed